Royal Bank of Canada
BCTX

Royal Bank of Canada’s Briacell Therapeutics BCTX Stock Holding History

Royal Bank of Canada’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
100
– – ﹤0.01% 7111
2025
Q4 		$1K Hold
100
– – ﹤0.01% 6964
2025
Q3 		$1K Sell
100
-7
-7% -$74 ﹤0.01% 6950
2025
Q2 		$3K Buy
107
+7
+7% +$255 ﹤0.01% 6722
2025
Q1 		$4K Buy
+100
New +$4.77K ﹤0.01% 6392
2024
Q4 		– Sell
-25
Closed -$5K – 6892
2024
Q3 		$5K Sell
25
-1
-4% -$112 ﹤0.01% 6485
2024
Q2 		$4K Buy
26
+2
+8% +$566 ﹤0.01% 6569
2024
Q1 		$10K Sell
24
-100
-81% -$55.1K ﹤0.01% 6188
2023
Q4 		$109K Buy
124
+100
+417% +$71.8K ﹤0.01% 5559
2023
Q3 		$23K Hold
24
– – ﹤0.01% 6122
2023
Q2 		$23K Buy
+24
New +$23.7K ﹤0.01% 6133
2023
Q1 		– Sell
-1
Closed -$1K – 7070
2022
Q4 		$1K Buy
+1
New +$847 ﹤0.01% 6999
2022
Q3 		– Sell
-1
Closed -$1K – 7436
2022
Q2 		$1K Buy
+1
New +$988 ﹤0.01% 7087
2022
Q1 		– Sell
-2
Closed -$3K – 7723
2021
Q4 		$3K Buy
+2
New +$2.62K ﹤0.01% 7322
2021
Q3 		– Hold
0
– – – 7624
2021
Q2 		– Hold
0
– – – 7471
2021
Q1 		– Hold
0
– – – 7414

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Royal Bank of Canada's BCTX Position: Q1 2026 in Review

Royal Bank of Canada held its Briacell Therapeutics (BCTX) position steady in Q1 2026 at 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7111.

Royal Bank of Canada first reported a position in BCTX in Q4 2021 and has held it in 14 quarters since. The position peaked at $109K in Q4 2023. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Royal Bank of Canada held 100 shares of Briacell Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada left its Briacell Therapeutics share count unchanged in Q1 2026.
  • Briacell Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7111 holding.
  • Royal Bank of Canada first reported a position in Briacell Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Royal Bank of Canada's Briacell Therapeutics position peaked at $109K in Q4 2023.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.